<DOC>
	<DOCNO>NCT01582945</DOCNO>
	<brief_summary>Ketamine infusion show rapid antidepressant property , however possible use ketamine treatment-resistant depression augmentation investigate . The overall aim study assess feasibility , safety tolerability , efficacy duration effect intravenous N-methyl-D-aspartate antagonist ketamine augmentation antidepressant chronic suicidal ideation subject severe treatment-resistant depression ( TRD ) . This open-label study ( pilot ) .</brief_summary>
	<brief_title>Ketamine Infusion Treatment-resistant Major Depressive Disorder</brief_title>
	<detailed_description>Patients undergo two week prospective observation , receive ketamine IV 0.5mg/kg 45 minute augmentation ongoing antidepressant regimen ; three infusion dose increased increase 0.75 mg/kg non-responders . The schedule administration twice week 3 week . After phase , patient follow assessment every two week three month . Total duration study 5 month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Outpatients severe treatmentresistant MDD Currently depress Currently regular psychiatric care On aggressive antidepressant regimen , stable 4 week No history major psychiatric illness , include bipolar disorder No history psychosis No history drug abuse No major medical illness unstable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Treatment resistant</keyword>
	<keyword>suicidal ideation</keyword>
	<keyword>major depressive disorder</keyword>
</DOC>